Corvus Pharmaceuticals (CRVS) Operating Expenses (2015 - 2026)

Corvus Pharmaceuticals' Operating Expenses history runs 12 years deep, the most recent figure standing at $14.9 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 49.94% year-over-year to $14.9 million; the TTM figure through Mar 2026 stood at $35.7 million (up 54.5% YoY), while the FY2023 annual figure was $23.4 million, down 28.12% from the prior year.
• Operating Expenses for Q1 2026 stood at $14.9 million, up from $10.6 million in the prior quarter.
• The five-year high for Operating Expenses was $14.9 million in Q1 2026, with the low at $5.6 million in Q3 2023.
• The 5-year median for Operating Expenses is $7.0 million (2022), against an average of $8.1 million.
• The sharpest annual moves came in 2023 and 2025: Operating Expenses slumped 55.42% in 2023, then surged 72.87% in 2025.
• Corvus Pharmaceuticals' Operating Expenses stood at $5.7 million in 2022, then fell by 0.26% to $5.7 million in 2023, then rose by 28.38% to $7.3 million in 2024, then jumped by 45.72% to $10.6 million in 2025, then jumped by 40.72% to $14.9 million in 2026.
• Business Quant data shows CRVS's Operating Expenses at $14.9 million in Q1 2026, $10.6 million in Q3 2025, and $10.3 million in Q2 2025.